Gyldenløve M - Search Results

1

Validation of psoriasis severity classification based on use of topical or systemic treatment.

Egeberg A, Gyldenløve M, Zachariae C, Skov L. Egeberg A, et al. Among authors: gyldenlove m. J Eur Acad Dermatol Venereol. 2018 Jan;32(1):e4-e5. doi: 10.1111/jdv.14427. Epub 2017 Jul 31. J Eur Acad Dermatol Venereol. 2018. PMID: 28646609 No abstract available.

2

Increased expression of glucagon-like peptide-1 receptors in psoriasis plaques.

Faurschou A, Pedersen J, Gyldenløve M, Poulsen SS, Holst JJ, Thyssen JP, Zachariae C, Vilsbøll T, Skov L, Knop FK. Faurschou A, et al. Among authors: gyldenlove m. Exp Dermatol. 2013 Feb;22(2):150-2. doi: 10.1111/exd.12081. Exp Dermatol. 2013. PMID: 23362875

3

[Psoriasis is associated with type 2 diabetes].

Gyldenløve M, Knop FK, Vilsbøll T, Zachariae C, Skov L. Gyldenløve M, et al. Ugeskr Laeger. 2013 Mar 4;175(10):652-4. Ugeskr Laeger. 2013. PMID: 23462038 Review. Danish.

4

Low prevalence of positive skin pathergy testing in Danish patients with Behçet's disease.

Gyldenløve M, Tvede N, Larsen JL, Jacobsen S, Thyssen JP. Gyldenløve M, et al. J Eur Acad Dermatol Venereol. 2014 Feb;28(2):259-60. doi: 10.1111/jdv.12189. Epub 2013 May 16. J Eur Acad Dermatol Venereol. 2014. PMID: 23676001 No abstract available.

5

Psoriasis and the Framingham risk score in a Danish hospital cohort.

Gyldenløve M, Jensen P, Linneberg A, Thyssen JP, Zachariae C, Hansen PR, Skov L. Gyldenløve M, et al. Int J Dermatol. 2014 Sep;53(9):1086-90. doi: 10.1111/ijd.12196. Epub 2013 Jul 24. Int J Dermatol. 2014. PMID: 23879194

6

Pseudoporphyria - a case report.

Gyldenløve M, Due E, Jonkman MF, Faurschou A. Gyldenløve M, et al. J Eur Acad Dermatol Venereol. 2015 Apr;29(4):827. doi: 10.1111/jdv.12433. Epub 2014 Mar 11. J Eur Acad Dermatol Venereol. 2015. PMID: 24612384 No abstract available.

7

'Short-term treatment with methotrexate does not affect microvascular endothelial function in patients with psoriasis'.

Gyldenløve M, Jensen P, Løvendorf MB, Zachariae C, Hansen PR, Skov L. Gyldenløve M, et al. J Eur Acad Dermatol Venereol. 2015 Mar;29(3):591-4. doi: 10.1111/jdv.12385. Epub 2014 Feb 21. J Eur Acad Dermatol Venereol. 2015. PMID: 24673617

8

MicroRNA-223 and miR-143 are important systemic biomarkers for disease activity in psoriasis.

Løvendorf MB, Zibert JR, Gyldenløve M, Røpke MA, Skov L. Løvendorf MB, et al. Among authors: gyldenlove m. J Dermatol Sci. 2014 Aug;75(2):133-9. doi: 10.1016/j.jdermsci.2014.05.005. Epub 2014 May 21. J Dermatol Sci. 2014. PMID: 24909097

9

Severe hypercalcaemia, nephrocalcinosis, and multiple paraffinomas caused by paraffin oil injections in a young bodybuilder.

Gyldenløve M, Rørvig S, Skov L, Hansen D. Gyldenløve M, et al. Lancet. 2014 Jun 14;383(9934):2098. doi: 10.1016/S0140-6736(14)60806-0. Lancet. 2014. PMID: 24931692 No abstract available.

10

Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients--a randomized placebo-controlled trial.

Faurschou A, Gyldenløve M, Rohde U, Thyssen JP, Zachariae C, Skov L, Knop FK, Vilsbøll T. Faurschou A, et al. Among authors: gyldenlove m. J Eur Acad Dermatol Venereol. 2015 Mar;29(3):555-9. doi: 10.1111/jdv.12629. Epub 2014 Aug 20. J Eur Acad Dermatol Venereol. 2015. PMID: 25139195 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

52 results

Search Page

Filters